Can Eye Surgery Help Alström Syndrome? What's Possible

Families newly diagnosed with Alström often ask whether surgery or some procedure could halt or reverse the progressive vision loss. The honest answer is that there is currently no surgery or approved treatment that addresses the underlying cone-rod dystrophy in Alström. A few specific procedures have a role in selected situations, and significant research is underway. This article covers what's currently possible, what's been tried, and what the research pipeline looks like.

There is no surgery or treatment available today that halts or reverses the cone-rod dystrophy that causes vision loss in Alström Syndrome.¹

What can sometimes be helpful in specific situations:

• Cataract removal, in adults who develop cataracts
• Treatment of complications (infections, raised eye pressure if it occurs)
• Symptom management with optical aids and tinted lenses

What's been tried but doesn't help:

• Most retinal prosthetics (Argus II and similar) have not been effective in Alström because the photoreceptor disease is widespread

What's in research:

• Gene therapy approaches targeting ALMS1
• Antisense oligonucleotides for specific variant types
• Cell-based therapies in early stages

Some adults with Alström develop cataracts (clouding of the lens of the eye) earlier than the general population, sometimes related to the metabolic complications of the syndrome. When cataracts significantly reduce any remaining functional vision or cause uncomfortable glare, cataract surgery can be considered.

Cataract surgery doesn't restore retinal function — it only removes the cloudy lens and replaces it with a clear artificial lens. So the procedure benefits people with Alström only when:

• They have residual retinal function that's being further obscured by the cataract
• The cataract is causing significant symptoms beyond the underlying retinal disease

A retinal specialist familiar with Alström can advise whether surgery is likely to help.²

The Argus II retinal prosthetic was the first FDA-approved retinal implant for retinitis pigmentosa. It and similar devices have generally not proven useful in Alström because:

• The cone-rod dystrophy in Alström is widespread, affecting most retinal photoreceptor cells
• Retinal implants work best when there's a discrete area of intact inner retina connected to viable optic nerve fibers
• The progressive degeneration in Alström extends beyond what current implants can compensate for

The Argus II was discontinued in 2019 due to manufacturer challenges, but newer implant designs are in development. None has yet shown specific benefit in Alström-related cone-rod dystrophy.

Gene therapy for Alström is in active research but faces specific challenges:

The size problem

The ALMS1 gene is large — coding for a protein of about 4,169 amino acids. Most gene-therapy approaches use adeno-associated virus (AAV) vectors that have a maximum cargo size of about 4.7 kb. The full ALMS1 coding sequence exceeds this limit. Researchers are exploring:

• Dual-vector strategies that split the gene across two AAV particles that recombine in cells
• Truncated minigenes that include only the most essential functional regions
• Alternative larger-capacity vectors beyond standard AAV

Targeting the right tissues

Even if a vector could deliver functional ALMS1, it would need to reach the photoreceptors specifically. Subretinal injection is the standard delivery method for retinal gene therapy and has been used successfully in other inherited retinal diseases (notably RPE65-related Leber Congenital Amaurosis with Luxturna).

Where the field stands

As of 2026, several research groups are pursuing ALMS1 gene therapy. Major efforts are underway in:

• Birmingham (UK) through a 3-year project starting in 2025 that is collaborating with Moorfields Eye Hospital and other ciliopathy centers
• Shanghai (China) at the National Center for Molecular Medicine using AAV and CRISPR-based approaches
• Several US and EU academic groups working on basic-science groundwork

None of these is yet at the human clinical-trial stage for ophthalmic indications, but the field is moving.³

For people with specific ALMS1 variants — particularly some splice-site mutations or nonsense mutations — antisense oligonucleotide drugs are theoretically applicable. ASOs work by binding to RNA and modulating splicing or translation. They've been used successfully in spinal muscular atrophy, some forms of Leber Congenital Amaurosis, and Duchenne muscular dystrophy.

ASO development for Alström is in early stages and would likely be variant-specific, benefiting some patients but not others.

Stem-cell-derived photoreceptor transplantation is in research for various retinal diseases. The cone-rod dystrophy of Alström would require not just photoreceptor replacement but addressing the underlying ALMS1 dysfunction in supporting cells. This is a longer-term direction.

While research progresses:

• Maintain regular ophthalmology surveillance — annual visits with ERG, OCT, fundus, visual fields where possible
• Use proven supports — tinted lenses, lighting adjustments, vision aids, Braille training, mobility services
• Connect with patient organizations — they track research and notify families when relevant trials open
• Consider participating in registries — natural-history data is essential for designing future trials
• Ask about clinical trials — your geneticist or ophthalmologist may know of relevant studies

We track the research pipeline in Alström Syndrome Research and Clinical Trials in 2026.

• Cone-Rod Dystrophy in Alström Syndrome
• Will My Child Go Blind From Alström Syndrome?
• Alström Syndrome Research and Clinical Trials in 2026
• How to Get Involved in Alström Syndrome Research

April 30, 2026.